Intas's successful and well recognized product basket also extends to its fully integrated Biotech Business. Intas-Biotech has well established domestic presence in Oncology & critical care with a basket of recombinant DNA technology based products.
Intas-Biotech is focused on production of high quality recombinant therapeutic proteins with fully backward integrated operations. Intas is the first Indian biopharmaceutical company to receive European Union-Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility.
The Biotech business has expertise in product development using various platforms including CHO based, E. coli based, Pegylation etc. The wide range of biotech products including growth factors, interferons, hormones, Monoclonal antibodies and plasma factors highlights its product development capabilities.
The company has state-of-the-art R&D division, cGMP-compliant multi-product manufacturing facility (for bulk as well as finished products) and multi-disciplinary team of scientists with expertise in transforming bench technology to commercial scale in shortest possible time.
The company has successfully launched five therapeutic recombinant proteins including Neukine® (rHu G-CSF), Erykine & Epofit (rHu EPO), Intalfa (rHu IFN Alfa-2b), Neupeg™ (Pegylated rHu G-CSF), world’s first Peg Filgrastim after the innovator and Terifrac (Parathyroid hormone). In addition to these products, there are more than 15 other recombinant molecules in the pipeline at various stages of development. The products developed at Intas Biotech are registered in more than 28 countries throughout the globe.
Intas-Biotech is focused on continuous development & enhancement of research pipeline to meet the increasing market demand. Leveraging its exceptional scientific talent pool and developmental capabilities, Intas is geared up to increase its presence in key thrust areas such as nephrology, rheumatology, oncology and plasma derived products.
For more information, please visit www.intasbiopharma.co.in